Cargando…
Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study
BACKGROUND: The COVID-19 pandemic caused by SARS-CoV-2 is causing ongoing human and socioeconomic losses. OBJECTIVE: To know how far the virus has spread in Niger State, Nigeria, a pilot study was carried out to determine the SARS-CoV-2 seroprevalence, patterns, dynamics, and risk factors in the sta...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595504/ https://www.ncbi.nlm.nih.gov/pubmed/37855218 http://dx.doi.org/10.2196/29587 |
_version_ | 1785124883144900608 |
---|---|
author | Majiya, Hussaini Aliyu-Paiko, Mohammed Balogu, Vincent Tochukwu Musa, Dickson Achimugu Salihu, Ibrahim Maikudi Kawu, Abdullahi Abubakar Bashir, Ishaku Yakubu Sani, Aishat Rabiu Baba, John Muhammad, Amina Tako Jibril, Fatimah Ladidi Bala, Ezekiel Obaje, Nuhu George Aliyu, Yahaya Badeggi Muhammad, Ramatu Gogo Mohammed, Hadiza Gimba, Usman Naji Uthman, Abduljelili Liman, Hadiza Muhammad Alhaji, Sule Alfa James, Joseph Kolo Makusidi, Muhammad Muhammad Isah, Mohammed Danasabe Abdullahi, Ibrahim Ndagi, Umar Waziri, Bala Bisallah, Chindo Ibrahim Dadi-Mamud, Naomi John Ibrahim, Kolo Adamu, Abu Kasim |
author_facet | Majiya, Hussaini Aliyu-Paiko, Mohammed Balogu, Vincent Tochukwu Musa, Dickson Achimugu Salihu, Ibrahim Maikudi Kawu, Abdullahi Abubakar Bashir, Ishaku Yakubu Sani, Aishat Rabiu Baba, John Muhammad, Amina Tako Jibril, Fatimah Ladidi Bala, Ezekiel Obaje, Nuhu George Aliyu, Yahaya Badeggi Muhammad, Ramatu Gogo Mohammed, Hadiza Gimba, Usman Naji Uthman, Abduljelili Liman, Hadiza Muhammad Alhaji, Sule Alfa James, Joseph Kolo Makusidi, Muhammad Muhammad Isah, Mohammed Danasabe Abdullahi, Ibrahim Ndagi, Umar Waziri, Bala Bisallah, Chindo Ibrahim Dadi-Mamud, Naomi John Ibrahim, Kolo Adamu, Abu Kasim |
author_sort | Majiya, Hussaini |
collection | PubMed |
description | BACKGROUND: The COVID-19 pandemic caused by SARS-CoV-2 is causing ongoing human and socioeconomic losses. OBJECTIVE: To know how far the virus has spread in Niger State, Nigeria, a pilot study was carried out to determine the SARS-CoV-2 seroprevalence, patterns, dynamics, and risk factors in the state. METHODS: A cross-sectional study design and clustered, stratified random sampling strategy were used to select 185 test participants across the state. SARS-CoV-2 IgG and IgM rapid test kits (colloidal gold immunochromatography lateral flow system) were used to determine the presence or absence of antibodies to the virus in the blood of sampled participants across Niger State from June 26 to 30, 2020. The test kits were validated using the blood samples of some of the Nigeria Center for Disease Control–confirmed positive and negative COVID-19 cases in the state. SARS-CoV-2 IgG and IgM test results were entered into the Epi Info questionnaire administered simultaneously with each test. Epi Info was then used to calculate the arithmetic mean and percentage, odds ratio, χ(2) statistic, and regression at a 95% CI of the data generated. RESULTS: The seroprevalence of SARS-CoV-2 in Niger State was found to be 25.4% (47/185) and 2.2% (4/185) for the positive IgG and IgM results, respectively. Seroprevalence among age groups, genders, and occupations varied widely. The COVID-19 asymptomatic rate in the state was found to be 46.8% (22/47). The risk analyses showed that the chances of infection are almost the same for both urban and rural dwellers in the state. However, health care workers, those who experienced flulike symptoms, and those who had contact with a person who traveled out of Nigeria in the last 6 months (February to June 2020) were at double the risk of being infected with the virus. More than half (101/185, 54.6%) of the participants in this study did not practice social distancing at any time since the pandemic started. Participants’ knowledge, attitudes, and practices regarding COVID-19 are also discussed. CONCLUSIONS: The observed Niger State SARS-CoV-2 seroprevalence and infection patterns meansuggest that the virus has widely spread, far more SARS-CoV-2 infections have occurred than the reported cases, and there is a high asymptomatic COVID-19 rate across the state. |
format | Online Article Text |
id | pubmed-10595504 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | JMIR Publications Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-105955042023-10-25 Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study Majiya, Hussaini Aliyu-Paiko, Mohammed Balogu, Vincent Tochukwu Musa, Dickson Achimugu Salihu, Ibrahim Maikudi Kawu, Abdullahi Abubakar Bashir, Ishaku Yakubu Sani, Aishat Rabiu Baba, John Muhammad, Amina Tako Jibril, Fatimah Ladidi Bala, Ezekiel Obaje, Nuhu George Aliyu, Yahaya Badeggi Muhammad, Ramatu Gogo Mohammed, Hadiza Gimba, Usman Naji Uthman, Abduljelili Liman, Hadiza Muhammad Alhaji, Sule Alfa James, Joseph Kolo Makusidi, Muhammad Muhammad Isah, Mohammed Danasabe Abdullahi, Ibrahim Ndagi, Umar Waziri, Bala Bisallah, Chindo Ibrahim Dadi-Mamud, Naomi John Ibrahim, Kolo Adamu, Abu Kasim JMIRx Med Original Paper BACKGROUND: The COVID-19 pandemic caused by SARS-CoV-2 is causing ongoing human and socioeconomic losses. OBJECTIVE: To know how far the virus has spread in Niger State, Nigeria, a pilot study was carried out to determine the SARS-CoV-2 seroprevalence, patterns, dynamics, and risk factors in the state. METHODS: A cross-sectional study design and clustered, stratified random sampling strategy were used to select 185 test participants across the state. SARS-CoV-2 IgG and IgM rapid test kits (colloidal gold immunochromatography lateral flow system) were used to determine the presence or absence of antibodies to the virus in the blood of sampled participants across Niger State from June 26 to 30, 2020. The test kits were validated using the blood samples of some of the Nigeria Center for Disease Control–confirmed positive and negative COVID-19 cases in the state. SARS-CoV-2 IgG and IgM test results were entered into the Epi Info questionnaire administered simultaneously with each test. Epi Info was then used to calculate the arithmetic mean and percentage, odds ratio, χ(2) statistic, and regression at a 95% CI of the data generated. RESULTS: The seroprevalence of SARS-CoV-2 in Niger State was found to be 25.4% (47/185) and 2.2% (4/185) for the positive IgG and IgM results, respectively. Seroprevalence among age groups, genders, and occupations varied widely. The COVID-19 asymptomatic rate in the state was found to be 46.8% (22/47). The risk analyses showed that the chances of infection are almost the same for both urban and rural dwellers in the state. However, health care workers, those who experienced flulike symptoms, and those who had contact with a person who traveled out of Nigeria in the last 6 months (February to June 2020) were at double the risk of being infected with the virus. More than half (101/185, 54.6%) of the participants in this study did not practice social distancing at any time since the pandemic started. Participants’ knowledge, attitudes, and practices regarding COVID-19 are also discussed. CONCLUSIONS: The observed Niger State SARS-CoV-2 seroprevalence and infection patterns meansuggest that the virus has widely spread, far more SARS-CoV-2 infections have occurred than the reported cases, and there is a high asymptomatic COVID-19 rate across the state. JMIR Publications Inc 2023-10-17 /pmc/articles/PMC10595504/ /pubmed/37855218 http://dx.doi.org/10.2196/29587 Text en © Hussaini Majiya, Mohammed Aliyu-Paiko, Vincent Tochukwu Balogu, Dickson Achimugu Musa, Ibrahim Maikudi Salihu, Abdullahi Abubakar Kawu, Ishaku Yakubu Bashir, Aishat Rabiu Sani, John Baba, Amina Tako Muhammad, Fatimah Ladidi Jibril, Ezekiel Bala, Nuhu George Obaje, Yahaya Badeggi Aliyu, Ramatu Gogo Muhammad, Hadiza Mohammed, Usman Naji Gimba, Abduljelili Uthman, Hadiza Muhammad Liman, Sule Alfa Alhaji, Joseph Kolo James, Muhammad Muhammad Makusidi, Mohammed Danasabe Isah, Ibrahim Abdullahi, Umar Ndagi, Bala Waziri, Chindo Ibrahim Bisallah, Naomi John Dadi-Mamud, Kolo Ibrahim, Abu Kasim Adamu. Originally published in JMIRx Med (https://med.jmirx.org), 17.10.2023. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIRx Med, is properly cited. The complete bibliographic information, a link to the original publication on https://med.jmirx.org/, as well as this copyright and license information must be included. |
spellingShingle | Original Paper Majiya, Hussaini Aliyu-Paiko, Mohammed Balogu, Vincent Tochukwu Musa, Dickson Achimugu Salihu, Ibrahim Maikudi Kawu, Abdullahi Abubakar Bashir, Ishaku Yakubu Sani, Aishat Rabiu Baba, John Muhammad, Amina Tako Jibril, Fatimah Ladidi Bala, Ezekiel Obaje, Nuhu George Aliyu, Yahaya Badeggi Muhammad, Ramatu Gogo Mohammed, Hadiza Gimba, Usman Naji Uthman, Abduljelili Liman, Hadiza Muhammad Alhaji, Sule Alfa James, Joseph Kolo Makusidi, Muhammad Muhammad Isah, Mohammed Danasabe Abdullahi, Ibrahim Ndagi, Umar Waziri, Bala Bisallah, Chindo Ibrahim Dadi-Mamud, Naomi John Ibrahim, Kolo Adamu, Abu Kasim Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study |
title | Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study |
title_full | Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study |
title_fullStr | Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study |
title_full_unstemmed | Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study |
title_short | Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study |
title_sort | seroprevalence of sars-cov-2 in niger state: pilot cross-sectional study |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595504/ https://www.ncbi.nlm.nih.gov/pubmed/37855218 http://dx.doi.org/10.2196/29587 |
work_keys_str_mv | AT majiyahussaini seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT aliyupaikomohammed seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT baloguvincenttochukwu seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT musadicksonachimugu seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT salihuibrahimmaikudi seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT kawuabdullahiabubakar seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT bashirishakuyakubu seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT saniaishatrabiu seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT babajohn seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT muhammadaminatako seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT jibrilfatimahladidi seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT balaezekiel seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT obajenuhugeorge seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT aliyuyahayabadeggi seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT muhammadramatugogo seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT mohammedhadiza seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT gimbausmannaji seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT uthmanabduljelili seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT limanhadizamuhammad seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT alhajisulealfa seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT jamesjosephkolo seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT makusidimuhammadmuhammad seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT isahmohammeddanasabe seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT abdullahiibrahim seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT ndagiumar seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT waziribala seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT bisallahchindoibrahim seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT dadimamudnaomijohn seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT ibrahimkolo seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy AT adamuabukasim seroprevalenceofsarscov2innigerstatepilotcrosssectionalstudy |